
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen Inc has demonstrated notable financial performance, with a 19% year-over-year revenue increase over the past nine months, driven by balanced growth in average selling prices (ASPs) and testing volumes. The company's ASPs have risen to $441 per test, reflecting a 9.2% increase year-over-year, which, despite current challenges, indicates positive momentum towards sustained financial growth. Additionally, Exagen has shown effective operational management, evident in its substantial share price appreciation of 133% year-to-date and a strategic expansion plan to increase its sales territories, further positioning the company for ongoing growth in the competitive diagnostics market.
Bears say
Exagen Inc. reported a top-line revenue of $17.2 million for the second quarter of 2025, which was a positive indicator, but the bottom-line results included a GAAP EPS loss of $0.21, falling short of the consensus estimate and reflecting ongoing financial challenges. The company has undergone significant cost-cutting measures, including a 42 full-time equivalent reduction across various departments, which raises concerns about its growth potential and ability to maintain sales momentum. Furthermore, despite having a backlog of $3.5 million, revenue is expected to remain inconsistent, leading to potential volatility in future earnings and reinforcing a negative outlook on the company's stock performance.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares